Thomas Lau

University tech transfer offices should stop trying to do the impossible, says Biofusion CEO David Baynes.

Every cloud has its silver lining. So if it wasn't for his daughter's diabetes, Anders Essen-Möller might not have sold his company and started Diamyd Medical AB.

A British pharmaceutical distributor, Beckpharma Ltd., said it licensed two Cuban healthcare products to sell in Europe as part of a broader effort for trade links.

It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?

Venture capital’s refusal to continue support helped Cyan Technology into liquidation. Rebuilt by its management, Cyan is now wary of asking VCs for money.

We interview Andrew Newland, head of a venture capital consultancy with a long-term strategy of working with scientists and inventors.

A British start-up is betting it has a better way for television networks to watch their viewers watching them.

Shares in Oxford BioMedica, an Oxford University spin-out, fell 8.3 percent on news that the company was seeking up to £30 million to fund the Phase III trial of its a TroVax cancer immunotherapy product.

A new research centre at Imperial Collegewill study urban energy efficiency and nuclear power generation.